Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail targets lung cancer brain metastases

NCT ID NCT06822543

Recruiting now Disease control Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a combination of three drugs—datopotamab deruxtecan, carboplatin, and pembrolizumab—in 46 people with non-small cell lung cancer that has spread to the brain and who have not had prior treatment for those brain tumors. The goal is to see how well the drugs shrink brain tumors. After four cycles, patients continue on two of the drugs until the disease gets worse or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
datopotamab deruxtecan, carboplatin, and pembrolizumab
What this could lead to
If successful, this combination could offer a new treatment option for lung cancer patients with brain metastases, potentially shrinking brain tumors and controlling the disease longer.
What could go wrong
This is a small, early-phase trial (46 people) with no control group, so results may not apply broadly. The drug combination can cause serious side effects, and it's unclear if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer lung cancer lung neoplasm metastatic malignant neoplasm in the brain non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES LUNG CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • A.C. Camargo Cancer Center

    RECRUITING

    São Paulo, São Paulo, 01509-001, Brazil

  • CPO - Centro Paulista de Oncologia (Oncoclínicas)

    RECRUITING

    São Paulo, São Paulo, 04538-135, Brazil

  • CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • CRIO - Centro Regional Integrado de Oncologia

    RECRUITING

    Fortaleza, Ceará, 60335-480, Brazil

  • CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)

    RECRUITING

    Rio de Janeiro, Rio de Janeiro, 22250-905, Brazil

  • Catarina Pesquisa Clínica - Clínica de Neoplasias Litoral

    RECRUITING

    Itajaí, South Carolina, 88301-220, Brazil

  • FUNFARME - Hospital de Base de São José do Rio Preto

    RECRUITING

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Hospital de Amor de Barretos

    RECRUITING

    Barretos, São Paulo, 14784-400, Brazil

  • IMIP - Instituto de Medicina Integral Professor Fernando Figueira

    RECRUITING

    Recife, Pernambuco, 50070-902, Brazil

  • ISCMPA - Santa Casa de Porto Alegre

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90050-170, Brazil

  • Liga Norte Riograndense Contra o Câncer

    RECRUITING

    Natal, Rio Grande do Norte, 59062-000, Brazil

  • Oncocentro de Minas Gerais (Oncoclínicas)

    RECRUITING

    Belo Horizonte, Minas Gerais, 30360-680, Brazil

  • Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel (Oncoclínicas)

    RECRUITING

    Salvador, Estado de Bahia, 40050-410, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.